| JAK3 facilitates the migration of breast cancer cells by store-operated calcium channel | [Janus kinase 3 facilitates the migration of breast cancer cells by store-operated calcium channel].
Liu X, Wei T, Gao ZD, Zhao XL, Wu HQ, Yan J. | 01/18/2020 |
| excreted-secreted antigens (ESA) directly influenced the expression of IL-2Rgamma, rather than the availability of IL-2 indirectly. ESA suppressed the level of Foxp3 via inhibiting IL-2Rgamma/JAK3/Stats signaling pathway in EL4 cells. | Excreted-secreted antigens of Toxoplasma gondii inhibit Foxp3 via IL-2Rγ/JAK3/Stats pathway.
Chen J, Huang C, Zhu D, Chen L, Wang J, Sun X, Hu L, Duan Y. | 11/30/2019 |
| The present results revealed that the JAK3/STAT3 oncogenic pathway and PRDM1 expression could stratify clinicopathologic features of extranodal NK/Tcell lymphoma, nasal type (ENNK/TNT). | JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type.
Liu J, Liang L, Li D, Nong L, Zheng Y, Huang S, Zhang B, Li T., Free PMC Article | 08/17/2019 |
| IL2RG/JAK3-deficient B cells remain intrinsically defective posttransplant despite follicular helper T-cell reconstitution. In vitro response of B cells to IL-21 is a potential biomarker for humoral immunity in patients with IL2RG/JAK3 SCID after transplantation. | B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.
Miggelbrink AM, Logan BR, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Abdel-Azim H, Prockop SE, Shyr D, Decaluwe H, Hanson IC, Gillio A, Dávila Saldaña BJ, Eibel H, Hopkins G, Walter JE, Whangbo JS, Kohn DB, Puck JM, Cowan MJ, Griffith LM, Haddad E, O'Reilly RJ, Notarangelo LD, Pai SY., Free PMC Article | 07/20/2019 |
| One-third of cases with JAK3 mutation harbor two JAK3 mutations and double JAK3 mutants show stronger signaling than single JAK3 mutants in patients with T-cell acute lymphoblastic leukemia (T-ALL). | Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Degryse S, Bornschein S, de Bock CE, Leroy E, Vanden Bempt M, Demeyer S, Jacobs K, Geerdens E, Gielen O, Soulier J, Harrison CJ, Constantinescu SN, Cools J., Free PMC Article | 07/13/2019 |
| JAK-1 and JAK-3 expression may play a role in the inflammatory processes in patients with ankylosing spondylitis. | Janus kinase-1 and 3 in ankylosing spondylitis.
Liao HT, Li TH, Chen CH, Chen HA, Chen WS, Lai CC, Chou CT, Tsai CY. | 03/9/2019 |
| JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene. | JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene.
Di Matteo G, Chiriaco M, Scarselli A, Cifaldi C, Livadiotti S, Di Cesare S, Ferradini V, Aiuti A, Rossi P, Finocchi A, Cancrini C., Free PMC Article | 12/22/2018 |
| identification of activating somatic mutations in JAK2 and germline mutations in JAK3 with clinical implications | Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
Li SD, Ma M, Li H, Waluszko A, Sidorenko T, Schadt EE, Zhang DY, Chen R, Ye F., Free PMC Article | 06/23/2018 |
| we report the results of a screening for mutations in SETBP1 and JAK3 of a cohort of seventy Italian patients with juvenile myelomonocytic leukemia, identifying 11.4% of them harboring secondary mutations in these two genes and discovering two new mutations in the SKI domain of SETBP1 | Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group.
Bresolin S, De Filippi P, Vendemini F, D'Alia M, Zecca M, Meyer LH, Danesino C, Locatelli F, Masetti R, Basso G, Te Kronnie G., Free PMC Article | 01/13/2018 |
| Jak3-mediated phosphorylation of beta-catenin suppressed EGF-mediated epithelial-mesenchymal transition and facilitated epithelial barrier functions by AJ localization of phosphorylated beta-catenin through its interactions with alpha-catenin. | Janus kinase 3 regulates adherens junctions and epithelial mesenchymal transition through β-catenin.
Mishra J, Das JK, Kumar N., Free PMC Article | 10/14/2017 |
| frequency of JAK3 mutations in the JH2 domain was relatively low in extranodal natural killer/T-cell lymphoma, nasal type (NTCL) in contrast to a previous report; study identified novel JAK3H583Y- and JAK3G589D-activating mutations that were oncogenic and sensitive to a JAK3 inhibitor | Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Sim SH, Kim S, Kim TM, Jeon YK, Nam SJ, Ahn YO, Keam B, Park HH, Kim DW, Kim CW, Heo DS. | 09/9/2017 |
| In natural killer/T-cell lymphoma (NKTL) as a disease model, phosphorylation of EZH2 by JAK3 promotes the dissociation of the PRC2 complex leading to decreased global histone H3 lysine 27 methylation levels. | EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.
Yan J, Li B, Lin B, Lee PT, Chung TH, Tan J, Bi C, Lee XT, Selvarajan V, Ng SB, Yang H, Yu Q, Chng WJ. | 08/5/2017 |
| a causal relationship between MLH1-deficiency and incidence of oncogenic point mutations in tyrosine kinases driving cell transformation and acquired resistance to kinase-targeted cancer therapies, is reported. | Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases.
Springuel L, Losdyck E, Saussoy P, Turcq B, Mahon FX, Knoops L, Renauld JC., Free PMC Article | 08/5/2017 |
| JAK3 mediates smooth muscle cell proliferation and survival during injury-induced vascular remodeling. | Janus Kinase 3, a Novel Regulator for Smooth Muscle Proliferation and Vascular Remodeling.
Wang YC, Cui XB, Chuang YH, Chen SY., Free PMC Article | 07/15/2017 |
| Data indicate that phosphorylation of Janus kinase 3 (JAK3) and STAT3 transcription factor (STAT3) was inhibited by latent membrane protein 1 (LMP1)-IgG. | A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.
Mao Y, Wang J, Zhang M, Fan W, Tang Q, Xiong S, Tang X, Xu J, Wang L, Yang S, Liu S, Xu L, Chen Y, Xu L, Yin R, Zhu J., Free PMC Article | 07/8/2017 |
| analysis of JAK3 kinetic mechanism and inhibition by tofacitinib | Insights into kinetic mechanism of Janus kinase 3 and its inhibition by tofacitinib.
Hekmatnejad M, Conwell S, Lok SM, Kutach A, Shaw D, Fang E, Swinney DC. | 05/13/2017 |
| patient had a homozygote of the JAK3 mutation, and her parents were heterozygous carriers. | Novel compound heterozygous mutations in a Japanese girl with Janus kinase 3 deficiency.
Sato T, Okano T, Tanaka-Kubota M, Kimura S, Miyamoto S, Ono S, Yamashita M, Mitsuiki N, Takagi M, Imai K, Kajiwara M, Ebato T, Ogata S, Oda H, Ohara O, Kanegane H, Morio T. | 04/8/2017 |
| JAK3 up-regulates SGLT1 activity by increasing the carrier protein abundance in the cell membrane, an effect enforcing cellular glucose uptake into activated lymphocytes and thus contributing to the immune response. | Expression of JAK3 Sensitive Na+ Coupled Glucose Carrier SGLT1 in Activated Cytotoxic T Lymphocytes.
Bhavsar SK, Singh Y, Sharma P, Khairnar V, Hosseinzadeh Z, Zhang S, Palmada M, Sabolic I, Koepsell H, Lang KS, Lang PA, Lang F. | 02/4/2017 |
| JAK3 and MCL-1 were down-regulated in patient CD8(+) T cells versus their normal counterparts, likely due to defective suppressor activity of miR-29b and miR-198 in RCC CD8(+) T cells. | miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.
Gigante M, Pontrelli P, Herr W, Gigante M, D'Avenia M, Zaza G, Cavalcanti E, Accetturo M, Lucarelli G, Carrieri G, Battaglia M, Storkus WJ, Gesualdo L, Ranieri E., Free PMC Article | 11/12/2016 |
| N225K and A550V PTPN6 mutations cause loss-of-function leading to JAK3 mediated deregulation of STAT3 pathway and uncover a mechanism that tumor cells can use to control PTPN6 substrate specificity. | Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Demosthenous C, Han JJ, Hu G, Stenson M, Gupta M., Free PMC Article | 11/12/2016 |
| Study shows JAK3 mutations in 16% of patients with T-cell prolymphocytic leukemia which might be an important prognostic marker. | Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.
Stengel A, Kern W, Zenger M, Perglerová K, Schnittger S, Haferlach T, Haferlach C. | 10/22/2016 |
| This study showed that JAK3 is a powerful negative regulator of the creatine transporter SLC6A8. | Regulation of the Na+,Cl- Coupled Creatine Transporter CreaT (SLC6A8) by the Janus Kinase JAK3.
Fezai M, Warsi J, Lang F. | 10/22/2016 |
| Letter/Case Report: ersistent rotavirus diarrhea post-transplant in a novel JAK3-SCID patient after vaccination. | Persistent rotavirus diarrhea post-transplant in a novel JAK3-SCID patient after vaccination.
Bogaert D, Van Schil K, Taghon T, Bordon V, Bonroy C, Dullaers M, De Baere E, Haerynck F. | 10/22/2016 |
| interleukin-4 regulates hematopoietic lineage choice by activating the JAK3-STAT6 pathway, which causes dendritic-cell-specific DNA demethylation. | External signals shape the epigenome.
Lennartsson A., Free PMC Article | 10/8/2016 |
| Foxp3 has a rapid turn over in Treg partly controlled at the transcriptional level by the JAK/STAT pathway | Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression.
Goldstein JD, Burlion A, Zaragoza B, Sendeyo K, Polansky JK, Huehn J, Piaggio E, Salomon BL, Marodon G., Free PMC Article | 08/27/2016 |